Taylor C P, Vartanian M G
Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, MI 48105.
Eur J Pharmacol. 1992 Mar 17;213(1):151-3. doi: 10.1016/0014-2999(92)90247-2.
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline) was studied following intravenous administration to mice. Maximal electroshock seizures were suppressed by low doses of NBQX (ED50 = 13 mg/kg) but effects had dissipated by 10 min after a dose of 25 mg/kg. Coadministration of the transport inhibitor probenecid (p-(dipropylsulphamoyl)-benzoic acid) enhanced and prolonged the anticonvulsant action of NBQX and also enhanced and prolonged ataxia. NBQX may be rapidly eliminated by a process sensitive to probenecid.
对小鼠静脉注射NBQX（2,3 - 二羟基 - 6 - 硝基 - 7 - 氨磺酰基 - 苯并(F)喹喔啉）后进行了研究。低剂量的NBQX（半数有效剂量 = 13毫克/千克）可抑制最大电休克惊厥，但在给予25毫克/千克剂量后10分钟，效果就已消失。同时给予转运抑制剂丙磺舒（对 -（二丙基氨磺酰基） - 苯甲酸）可增强并延长NBQX的抗惊厥作用，同时也增强并延长了共济失调。NBQX可能通过一个对丙磺舒敏感的过程被快速清除。
